SCHEDULE 13G/A: BlackRock Maintains Significant 8.4% Stake in Veracyte, Inc.
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 8.4% of Veracyte, Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 6,558,952 shares of Veracyte, Inc. common stock.
- This ownership represents 8.4% of Veracyte, Inc.'s outstanding common stock.
- BlackRock holds sole voting power over 6,355,351 shares and sole dispositive power over 6,558,952 shares.
- The filing is an Amendment No. 15 to a Schedule 13G, indicating a routine update to a previously disclosed passive investment position.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Veracyte, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative operational or financial news about the issuer.
Positives
- BlackRock, a major institutional investor, maintaining an 8.4% stake in Veracyte, Inc. signals continued confidence in the company.
Negatives
- The document does not present any specific negative information regarding Veracyte, Inc.'s operations or financial performance.
Risks
- The Schedule 13G filing itself does not detail specific operational, financial, or strategic risks for Veracyte, Inc.; it is a disclosure of beneficial ownership.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment by a large asset manager, BlackRock, in a publicly traded company, Veracyte, Inc. It reflects BlackRock's ongoing portfolio management activities rather than a specific strategic move related to Veracyte's industry position.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence investor perception and market liquidity.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution for the Power of Attorney document. |
| 03/31/2025 | Date of event which requires the filing of this statement (reporting date for ownership). |
| 04/17/2025 | Date of signature for the Schedule 13G filing. |
Keywords
BlackRock, Veracyte Inc., Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.